Levodopa Benefits Neovascular Age-Related Macular Degeneration
TUESDAY, Sept. 15, 2020 -- Levodopa is a safe and well-tolerated treatment for neovascular age-related macular degeneration (nAMD) and improves visual outcomes, according to a study recently published in The American Journal of Medicine. Anna G.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2020 Category: Pharmaceuticals Source Type: news

Levodopa may improve vision in patients with macular degeneration
(Elsevier) Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized and improved their vision. It reduced the number of treatments necessary to maintain vision, and as such, will potentially reduce the burden of treating the disease, financially and otherwise. Their findings appear in The American Journal of Medicine, published by Elsevier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

Oleh Hornykiewicz, Who Discovered Parkinson ’s Treatment, Dies at 93
His research into dopamine led to the mainstay treatment still used today to treat millions of people with Parkinson ’s. (Source: NYT Health)
Source: NYT Health - June 13, 2020 Category: Consumer Health News Authors: Sam Roberts Tags: Parkinson ' s Disease Dopamine Deaths (Obituaries) Research Hornykiewicz, Oleh L-dopa Levodopa Source Type: news

FDA Clears Opicapone (Ongentys) as Add-On Therapy in PD FDA Clears Opicapone (Ongentys) as Add-On Therapy in PD
Opicapone is an oral COMT inhibitor approved as add-on therapy for patients with Parkinson disease who experience'off'periods while receiving a stable levodopa/carbidopa regimen.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 28, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS(R) (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
ONGENTYS, the First and Only Approved Once-Daily COMT Inhibitor, Decreases "Off" Time and Increases "On" Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa in Patients with Parkinson's Disease Neurocrine Biosciences... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, ONGENTYS, opicapone, Parkinson's Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 27, 2020 Category: Pharmaceuticals Source Type: news

Accidental Modopar poisoning in a two-year-old child: a case report - Lahlou A, Benlamkaddem S, Berdai MA, Harandou M.
Levodopa is a dopamine precursor and a mainstay treatment in the management of Parkinson's disease. Its side effects induce dyskinesia, nausea, vomiting, and orthostatic hypotension. Acute levodopa acute poisoning is uncommon, with only a few reported case... (Source: SafetyLit)
Source: SafetyLit - January 11, 2020 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

levodopa-carbidopa, Sinemet, Sinemet CR, Parcopa
Title: levodopa-carbidopa, Sinemet, Sinemet CR, ParcopaCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/17/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 17, 2019 Category: Drugs & Pharmacology Source Type: news

RightEye Has “Breakthrough” in Its Vision for Parkinson’s Test
There could soon be an eye test to aid in the assessment of Parkinson’s disease. FDA has recently granted breakthrough device designation to a technology designed by RightEye that uses objective eye movement measurements to help detect the neurological disease. If the RightEye Vision System could gain a nod from FDA for detection, it would be a gamechanger because currently, no single test is capable of definitively diagnosing Parkinson's disease. Doctors instead rely on a variety of neurological examinations designed to confirm the clinical diagnosis, and misdiagnosis remains a continuing iss...
Source: MDDI - December 3, 2019 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news

Vitamins for Depression
In trying to cope with the debilitating symptoms of depression, people often turn to vitamins, supplements, herbs, or home remedies first. And it’s no wonder — such efforts to alleviate symptoms are often far less expensive and easier to obtain. For some, it may be a part of their rationalization that their depression “isn’t all that bad,” if it can be treated with vitamins and supplements. Many people find relief in taking vitamins and supplements for depression. It is also one of the most well-researched topics, so we know what the science has to say about the efficacy of such treatments. Bu...
Source: Psych Central - September 3, 2019 Category: Psychiatry Authors: John M. Grohol, Psy.D. Tags: Depression Diet & Nutrition General Medications Miscellaneous Drugs supplements for depression vitamins for depression Source Type: news

Nourianz Approved to Treat'Off' Episodes in Parkinson Disease
WEDNESDAY, Aug. 28, 2019 -- Nourianz (istradefylline) tablets have been approved as an add-on treatment to levodopa/carbidopa for adults with Parkinson disease experiencing " off " episodes, the U.S. Food and Drug Administration announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 28, 2019 Category: General Medicine Source Type: news

FDA OKs Istradefylline for Parkinson's Disease'Off' Episodes FDA OKs Istradefylline for Parkinson's Disease'Off' Episodes
Oral istradefylline (Nourianz) reduces"off" episodes when added to levodopa/carbidopa in patients with Parkinson's disease.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 28, 2019 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson ’s Disease
August 27, 2019 -- The U.S. Food and Drug Administration today approved Nourianz (istradefylline) tablets as an add-on treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing " off " episodes. An " off " ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 28, 2019 Category: Drugs & Pharmacology Source Type: news

A Wearable Device Is Changing the Way Clinicians Manage Parkinson & #039;s Patients
A recently published study in Functional Neurology suggests that using data from an FDA-cleared watch-like device called the Personal KinetiGraph (PKG) provides an objective and more effective approach to assessing motor fluctuations in patients with Parkinson's disease (PD) compared with patient-reported motor diaries. “Motor fluctuations, including 'wearing-off' and dyskinesia, are associated with increased disease severity and disability, and PD patients experience decreased quality of life as their response to medical therapy becomes less predictable,” said EchoÂ&nb...
Source: MDDI - August 2, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Source Type: news

CHMP Backs Inhaled Levodopa (Inbrija) for Parkinson's'Off' Episodes CHMP Backs Inhaled Levodopa (Inbrija) for Parkinson's'Off' Episodes
Levodopa inhalation powder is safe and effective in improving motor function during'off'periods in patients with Parkinson's disease.International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 26, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Freezing of gait and postural instability: the unpredictable response to levodopa in Parkinson's disease - Moreira F, Rebelo Gomes I, Janu ário C.
Freezing of gait (FOG) and postural instability are challenging motor symptoms that present a serious therapeutic dilemma in Parkinson's disease. Appropriate distinction between FOG subtypes may be difficult during routine clinical visits, as shown in the ... (Source: SafetyLit)
Source: SafetyLit - July 26, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
JERUSALEM, July 22, 2019 -- (Healthcare Sales & Marketing Network) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating ... Biopharmaceuticals, Neurology Intec Pharma, Accordion Pill, Carbidopa, Levodopa, Parkinson's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2019 Category: Pharmaceuticals Source Type: news

Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
The human gut microbiota metabolizes the Parkinson’s disease medication Levodopa (l-dopa), potentially reducing drug availability and causing side effects. However, the organisms, genes, and enzymes responsible for this activity in patients and their susceptibility to inhibition by host-targeted drugs are unknown. Here, we describe an interspecies pathway for gut bacterial l-dopa metabolism. Conversion of l-dopa to dopamine by a pyridoxal phosphate-dependent tyrosine decarboxylase from Enterococcus faecalis is followed by transformation of dopamine to m-tyramine by a molybdenum-dependent dehydroxylase from Eggerthell...
Source: ScienceNOW - June 13, 2019 Category: Science Authors: Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., Balskus, E. P. Tags: Chemistry, Microbiology, Online Only r-articles Source Type: news

DUOGLOBE Interim Results: Intestinal Gel Cuts PD'Off' Time DUOGLOBE Interim Results: Intestinal Gel Cuts PD'Off' Time
Researchers release additional results looking at levodopa-carbidopa intestinal gel to help lessen motor fluctuations and dyskinesia in people with advanced Parkinson's disease.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 6, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Attempted suicide in a Parkinsonian patient treated with DBS of the VIM and high dose carbidopa-levodopa - Ayobello A, Saway B, Greenage M.
INTRODUCTION: Parkinson's disease (PD) is a complex disease that is often treated with dopaminergic medications such as carbidopa-levodopa and now with innovative interventions such as deep brain stimulation (DBS). While PD frequently presents with depress... (Source: SafetyLit)
Source: SafetyLit - May 1, 2019 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Levodopa for Early PD: Not Protective, But Not Harmful (CME/CE)
(MedPage Today) -- Trial shows no disease-modifying or negative effects at 80 weeks (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 29, 2019 Category: Neurology Source Type: news

Inhaled Levodopa Improves Motor Scores During PD'Off' Periods Inhaled Levodopa Improves Motor Scores During PD'Off' Periods
Levodopa inhalation powder is safe and effective in improving motor function during'off'periods in patients with Parkinson's disease, suggest newly published results from the phase 3 SPAN-PD trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

No Effect of Levodopa on Parkinson's Progression No Effect of Levodopa on Parkinson's Progression
Use of levodopa in early Parkinson's disease does not have any disease-modifying effect, either beneficial or detrimental, a new study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Early Levodopa Neither Protective Nor Harmful in Parkinson ’s
(MedPage Today) -- Early treatment shows no disease-modifying effect at 80 weeks (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 24, 2019 Category: Neurology Source Type: news

Levodopa & #43; Carbidopa Does Not Modify Disease in Early Parkinson
THURSDAY, Jan. 24, 2019 -- For patients with early Parkinson disease, treatment with levodopa combined with carbidopa has no disease-modifying effect, according to a study published in the Jan. 24 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 24, 2019 Category: Pharmaceuticals Source Type: news

Dopamine modulates the reward experiences elicited by music
(IDIBELL-Bellvitge Biomedical Research Institute) Researchers from IDIBELL-UB, the Sant Pau Hospital and the McGill University published a new study in PNAS that shows for the first time a causal link between the dopaminergic system and enjoying music. Dopamine precursor levodopa increased the musical pleasure and music-related motivational responses, such as willingness to purchase a song, while the dopamine antagonist risperidone led to a reduction of both. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 24, 2019 Category: International Medicine & Public Health Source Type: news

Dopamine modulates reward experiences elicited by music
(University of Barcelona) New study in Proceedings of the National Academy of Science reveals causal link between dopamine and human reward response to music listening. Researchers pharmacologically manipulated dopaminergic transmission of 27 participants while listening to music and showed causal link between dopamine and pleasure. While levodopa increased hedonic experience and motivation, risperidone led to a reduction of both. These results shed light on neurobiology and neurochemistry underpinning reward responses, contributing to an open debate on human pleasures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 24, 2019 Category: International Medicine & Public Health Source Type: news

Good News, Bad News on Levodopa for Parkinson's Disease
WEDNESDAY, Jan. 23, 2019 -- The most potent drug available for Parkinson's disease, levodopa, treats symptoms of the disease but does nothing to either ease or increase its still-mysterious underlying causes, a new clinical trial has... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 23, 2019 Category: General Medicine Source Type: news

How gut bacteria affect the treatment of Parkinson's disease
(University of Groningen) Patients with Parkinson's disease are treated with levodopa, which is converted into dopamine, a neurotransmitter in the brain. In a study published on Jan. 18, in the journal Nature Communications, scientists from the University of Groningen show that gut bacteria can metabolize levodopa into dopamine. As dopamine cannot cross the blood-brain barrier, this makes the medication less effective -- even in the presence of inhibitors that should prevent the conversion of levodopa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 18, 2019 Category: International Medicine & Public Health Source Type: news

Inbrija (Levodopa Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 7, 2019 Category: Drugs & Pharmacology Source Type: news

Acorda nabs crucial FDA ok for Parkinson ’s drug
Acorda Therapeutics announced that the U.S. FDA approved Inbrija for intermittent treatment of OFF episodes in people with Parkinson ’s disease treated with carbidopa/levodopa. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 27, 2018 Category: Pharmaceuticals Source Type: news

Acorda wins FDA nod for inhaled Parkinson ’ s therapy
Acorda Therapeutics (NSDQ:ACOR) said this week that the FDA approved its Inbrija device for the intermittent treatment of  “off” episodes in people with Parkinson’s disease. The self-administered, inhaled therapy is designed for people experiencing a re-emergence of Parkinson’s symptoms. These “off” episodes are caused by low levels of dopamine between doses of the standard oral Parkinson’s therapy, carbidopa/levodopa, according to Acorda. Get the full story at our sister site, Drug Delivery Business News. The post Acorda wins FDA nod for inhaled Parkinson’s therapy...
Source: Mass Device - December 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Featured Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Acorda Therapeutics Source Type: news

FDA Approves Inhaled Levodopa for Parkinson's
(MedPage Today) -- Improved motor function when taken during'off'episodes (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 26, 2018 Category: American Health Source Type: news

FDA OKs Inhaled Levodopa (Inbrija) for Parkinson's'Off' Episodes FDA OKs Inhaled Levodopa (Inbrija) for Parkinson's'Off' Episodes
Levodopa inhalation powder aims to fill an unmet need for roughly 40% of patients with Parkinson's who experience off periods while taking an oral regimen of carbidopa-levodopa.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 24, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Inbrija (levodopa inhalation powder) for Intermittent Treatment of OFF Episodes in People with Parkinson ’s Disease
ARDSLEY, N.Y.--(BUSINESS WIRE) December 21, 2018 --Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration approved Inbrija™ for intermittent treatment of OFF episodes in people with Parkinson’s disease... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 21, 2018 Category: Drugs & Pharmacology Source Type: news

' Accordion' Pill May Reduce Levodopa Fluctuations in PD'Accordion' Pill May Reduce Levodopa Fluctuations in PD
A pill that releases an accordion-folded sheet in the stomach prolongs gastroretention of the device and thus, prolonged delivery of drugs to the upper GI tract, where some drugs are absorbed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 7, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

FDA pushes back decision date for Acorda ’s Parkinson’s drug
Acorda Therapeutics (NSDQ:ACOR) said today that the FDA pushed back its goal date for the agency’s review of Acorda’s inhaled levodopa Parkinson’s therapy. The FDA’s date to make a decision about Acorda’s Inbrija product was moved from Oct. 5, 2018 to Jan. 5, 2019. The Ardsley, N.Y.-based company said the extension is related to submissions it made in response to requests from the FDA for additional data on chemistry, manufacturing & controls. Get the full story at our sister site, Drug Delivery Business News. The post FDA pushes back decision date for Acorda’s Parkinson’s...
Source: Mass Device - September 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Acorda Therapeutics Source Type: news

Amneal Initiates Phase 3 Study for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa (CD-LD) in Advanced Parkinson's Disease Patients
BRIDGEWATER, N.J., May 7, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal (NYSE: AMRX), a specialty pharmaceutical company, today announced it has initiated a Phase 3 trial for IPX203. The IPX203 Phase 3 protocol has been agreed upon with the Foo... Biopharmaceutical, Neurology Amneal Pharmaceuticals, Parkinson's Disease, carbidopa, levodopa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 7, 2018 Category: Pharmaceuticals Source Type: news

Boston Sci Sees Strong Data From Parkinson & #039;s Treatment Study
This study meets a new level of rigor in evaluating the effectiveness of a DBS system," Jerrold Vitek, MD, Phd, McKnight professor and chair, Department of Neurology, University of Minnesota Medical School and coordinating principal investigator for the INTREPID study, said in a release. "The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System." Boston Scientific received FDA approval for Vercise late last year. The device...
Source: MDDI - April 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

Boston Scientific touts 1-year data on Vercise DBS in Parkinson ’ s
This study meets a new level of rigor in evaluating the effectiveness of a DBS system,” coordinating principal investigator Dr. Jerrold Vitek, of the University of Minnesota Medical School, said in prepared remarks. “The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System.” Vercise won CE Mark approval in the European Union to treat essential tremor in 2014. FDA approval to treat Parkinson’s followed las...
Source: Mass Device - April 24, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Boston Scientific Parkinson's disease Source Type: news

Intec Pharma partners for manufacture of ‘ accordion pill ’ for Parkinson ’ s disease
Intec Pharma (NSDQ:NTEC) plans to partner with LTS to manufacture the company’s lead product candidate – an oral pill for Parkinson’s disease formulated with Intec’s “Accordion Pill” drug delivery tech. According to the terms of the deal, LTS will manufacture the carbidopa/levodopa capsules using Intec’s production technology in LTS’ manufacturing facility in Germany. Get the full story at our sister site, Drug Delivery Business News. The post Intec Pharma partners for manufacture of ‘accordion pill’ for Parkinson’s disease appeared first on MassDevice....
Source: Mass Device - March 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat Intec Pharma Source Type: news

Acorda Therapeutics wins FDA NDA nod for Inbrija
Acorda Therapeutics (NSDQ:ACOR) said today that the FDA accepted the New Drug Application for its Inbrija investigational inhaled levodopa product designed for treating symptoms of OFF periods in patients with Parkinson’s disease who are taking carbidopa/levodopa regimens. The approval comes with a target date of October 5, 2018, the Ardsley, N.Y.-based company said. Read the whole story at our sister site, Drug Delivery Business The post Acorda Therapeutics wins FDA NDA nod for Inbrija appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Neurological Regulatory/Compliance Respiratory Acorda Therapeutics Source Type: news

Acorda Announces FDA Acceptance of New Drug Application for Inbrija (levodopa inhalation powder)
ARDSLEY, N.Y.--(BUSINESS WIRE) February 20, 2018 -- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for Inbrija. Inbrija is an... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 20, 2018 Category: Drugs & Pharmacology Source Type: news

Stalevo (Carbidopa, Levodopa and Entacapone) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2017 Category: Drugs & Pharmacology Source Type: news

Acorda Resubmits New Drug Application for Inbrija (CVT-301, levodopa inhalation powder)
ARDSLEY, N.Y.--(BUSINESS WIRE) December 7, 2017 -- Acorda Therapeutics (Nasdaq:ACOR) announced the resubmission of its New Drug Application (NDA) for Inbrija to the U.S. Food and Drug Administration (FDA). Inbrija is an investigational treatment for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 7, 2017 Category: Drugs & Pharmacology Source Type: news

Duopa (Carbidopa and Levodopa Enteral Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 13, 2017 Category: Drugs & Pharmacology Source Type: news

Carbidopa and Levodopa Extended Release Tablets (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 29, 2017 Category: Drugs & Pharmacology Source Type: news

Medical News Today: Pancreatic cancer could be treated with a Parkinson's drug
Carbidopa, commonly used together with L-Dopa to treat Parkinson's disease, was found to stop tumor growth in mice and human cancer lines. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 29, 2017 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news

Pancreatic cancer could be treated with a Parkinson's drug
Carbidopa, commonly used together with L-Dopa to treat Parkinson's disease, was found to stop tumor growth in mice and human cancer lines. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - September 29, 2017 Category: Neurology Tags: Pancreatic Cancer Source Type: news

Carbidopa and Levodopa Extended Release Tablets (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 27, 2017 Category: Drugs & Pharmacology Source Type: news

Calvin ’s gift: Second opinion provides answers and hope
It’s not often that parents breathe a sigh of relief when their child is diagnosed with a chronic, potentially debilitating condition. But that sense of peace is just what Paula and Scott Hurd felt when they were told that their son, Calvin, had a rare movement disorder. “We were so happy to finally understand what was happening,” says Paula. Slipping away The search for answers had begun several years earlier, when Calvin started limping. At first, his family thought he had simply tripped over something and injured himself. But when he didn’t improve, they took him to the doctor. A series of appoi...
Source: Thrive, Children's Hospital Boston - September 13, 2017 Category: Pediatrics Authors: Jessica Cerretani Tags: Diseases & Conditions Our Patients’ Stories cerebral palsy Cerebral Palsy Program Dr. Benjamin Shore Dr. David Coulter dystonia Second opinion Source Type: news